What's to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease?

Prion

Volumn 7, Issue 1, 2013, Pages 92-97

  Dunning, Christopher J R ^a   George, Sonia ^a   Brundin, Patrik ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Alpha synuclein; Cell to cell transfer; Parkinson disease; Prion like; Protein misfolding

Indexed keywords

ALPHA SYNUCLEIN; PRION PROTEIN;

CONFERENCE PAPER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; LEWY BODY; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN FOLDING;

ALPHA-SYNUCLEIN; CELL-TO-CELL TRANSFER; PARKINSON DISEASE; PRION-LIKE; PROTEIN MISFOLDING;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; HUMANS; LEWY BODIES; MITOCHONDRIA; OXIDATIVE STRESS; PARKINSON DISEASE; PRIONS; PROTEIN FOLDING;

EID: 84874594129     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.23806     Document Type: Conference Paper

References (83)

1. Lewy FH. Paralysis agitans. I. Pathologische Anatomie. In: Lewandowski M, ed. Handbuch der Neurologie, Band III. Berlin: Springer 1912.
2. Leverenz JB, Umar I, Wang Q, Montine TJ, McMillan PJ, Tsuang DW, et al. Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol 2007; 17:139-45; PMID:17388944; http://dx.doi.org/10.1111/j.1750-3639.2007. 00048.x.
3. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388:839-40; PMID:9278044; http://dx.doi.org/10.1038/42166.
4. Jellinger KA. The role of α-synuclein in neurodegeneration- An update. Transl Neurosci. 2012; 3:75-122; http://dx.doi.org/10.2478/s13380-012- 0013-1.
5. Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE. alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem 2000; 275:34328- 34; PMID:10915790; http://dx.doi.org/10.1074/jbc.M004345200.
6. Dikiy I, Eliezer D. Folding and misfolding of alphasynuclein on membranes. Biochim Biophys Acta 2012; 1818:1013-8; PMID:21945884; http://dx.doi.org/10.1016/j.bbamem.2011.09.008.
7. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A 2000; 97:4897- 902; PMID:10781096; http://dx.doi.org/10.1073/pnas.97.9.4897.
8. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4:160-4; PMID:11813001.
9. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7; PMID:9197268; http://dx.doi.org/10.1126/ science.276.5321.2045.
10. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18:106-8; PMID:9462735; http://dx.doi.org/10.1038/ ng0298-106.
11. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55:164- 73; PMID:14755719; http://dx.doi.org/10. 1002/ana.10795.
12. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364:1167-9; PMID:15451224; http://dx.doi.org/10.1016/ S0140-6736(04)17103-1.
13. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302:841; PMID:14593171; http://dx.doi.org/10.1126/science.1090278.
14. Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 2008; 22:1327-34; PMID:18162487; http://dx.doi.org/10. 1096/fj.07-9348com.
15. Chu Y, Kordower JH. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis 2007; 25:134- 49; PMID:17055279; http://dx.doi.org/10.1016/j.nbd.2006.08.021.
16. Li W, Lesuisse C, Xu Y, Troncoso JC, Price DL, Lee MK. Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. J Neurosci 2004; 24:7400-9; PMID:15317865; http://dx.doi.org/10.1523/ JNEUROSCI.1370-04.2004.
17. Collier TJ, Kanaan NM, Kordower JH. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci 2011; 12:359-66; PMID:21587290; http://dx.doi.org/10.1038/nrn3039.
18. Olanow CW, Perl DP, DeMartino GN, McNaught KSP. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004; 3:496-503; PMID:15261611; http://dx.doi.org/10.1016/S1474-4422(04)00827-0.
19. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004; 279:4625-31; PMID:14627698; http://dx.doi.org/10.1074/jbc.M310994200.
20. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord 2011; 26:1049- 55; PMID:21626550; http://dx.doi.org/10.1002/mds. 23732.
21. Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat Rev Neurosci 2002; 3:932-42; PMID:12461550; http://dx.doi.org/10.1038/nrn983.
22. Wersinger C, Sidhu A. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci Lett 2003; 340:189-92; PMID:12672538; http://dx.doi.org/10.1016/S0304-3940(03)00097-1.
23. Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 2006; 26:11915-22; PMID:17108165; http://dx.doi.org/10.1523/JNEUROSCI.3821-06. 2006.
24. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010; 65:66-79; PMID:20152114; http://dx.doi.org/10.1016/j.neuron.2009.12.023.
25. Lotharius J, O'Malley KL. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 2000; 275:38581-8; PMID:10969076; http://dx.doi.org/10.1074/jbc.M005385200.
26. Lee HJ, Baek SM, Ho DH, Suk JE, Cho ED, Lee SJ. Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Exp Mol Med 2011; 43:216-22; PMID:21415592; http://dx.doi.org/10.3858/emm.2011.43.4.026.
27. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001; 294:1346-9; PMID:11701929; http://dx.doi.org/10.1126/science. 1063522.
28. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000; 157:401-10; PMID:10934145; http://dx.doi.org/10.1016/S0002-9440(10)64553- 1.
29. Cremades N, Cohen SIA, Deas E, Abramov AY, Chen AY, Orte A, et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 2012; 149:1048-59; PMID:22632969; http://dx.doi.org/10. 1016/j.cell.2012.03.037.
30. Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J Biol Chem 1999; 274:28849-52; PMID:10506125; http://dx.doi.org/10. 1074/jbc.274.41.28849.
31. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000; 290:985- 9; PMID:11062131; http://dx.doi.org/10.1126/science.290.5493.985.
32. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54:823-7; PMID:2154550; http://dx.doi.org/10.1111/j.1471-4159.1990.tb02325.x.
33. Autere J, Moilanen JS, Finnilä S, Soininen H, Mannermaa A, Hartikainen P, et al. Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia. Hum Genet 2004; 115:29-35; PMID:15108120; http://dx.doi.org/10.1007/s00439-004-1123-9.
34. Pyle A, Foltynie T, Tiangyou W, Lambert C, Keers SM, Allcock LM, et al. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann Neurol 2005; 57:564-7; PMID:15786469; http://dx.doi.org/10.1002/ana.20417.
35. Valente EM, Arena G, Torosantucci L, Gelmetti V. Molecular pathways in sporadic PD. Parkinsonism Relat Disord 2012; 18(Suppl 1):S71-3; PMID:22166460; http://dx.doi.org/10.1016/S1353-8020(11)70023-2.
36. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008; 283:9089-100; PMID:18245082; http://dx.doi.org/10.1074/jbc.M710012200.
37. Xie W, Chung KKK. Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease. J Neurochem 2012; 122:404-14; PMID:22537068; http://dx.doi.org/10.1111/j.1471-4159.2012.07769.x.
38. Calì T, Ottolini D, Negro A, Brini M. α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum- mitochondria interactions. J Biol Chem 2012; 287:17914-29; PMID:22453917; http://dx.doi.org/10.1074/jbc.M111.302794.
39. Chinta SJ, Mallajosyula JK, Rane A, Andersen JK. Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 2010; 486:235-9; PMID:20887775; http://dx.doi.org/10.1016/j.neulet.2010.09.061.
40. Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K, et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem 2011; 286:20710-26; PMID:21489994; http://dx.doi.org/10.1074/jbc.M110.213538.
41. Kamp F, Exner N, Lutz AK, Wender N, Hegermann J, Brunner B, et al. Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J 2010; 29:3571-89; PMID:20842103; http://dx.doi.org/10. 1038/emboj.2010.223.
42. Esteves AR, Arduíno DM, Swerdlow RH, Oliveira CR, Cardoso SM. Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson's disease cybrids. Antioxid Redox Signal 2009; 11:439- 48; PMID:18717628; http://dx.doi.org/10.1089/ars.2008.2247.
43. Lema Tomé CM, Tyson T, Rey NL, Grathwohl S, Britschgi M, Brundin P. Inflammation and α-Synuclein's Prion-like Behavior in Parkinson's Disease-Is There a Link? Mol Neurobiol 2012; PMID:22544647; http://dx.doi.org/ 10.1007/s12035-012-8267-8.
44. Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol 2003; 54:283- 6; PMID:12953260; http://dx.doi.org/10.1002/ana.10675.
45. Greggio E, Civiero L, Bisaglia M, Bubacco L. Parkinson's disease and immune system: is the culprit LRRKing in the periphery? J Neuroinflammation 2012; 9:94; PMID:22594666; http://dx.doi.org/10.1186/1742-2094-9-94.
46. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005; 19:533-42; PMID:15791003; http://dx.doi.org/10.1096/fj.04-2751com.
47. Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 2008; 67:1149-58; PMID:19018246; http://dx.doi.org/10.1097/NEN.0b013e31818e5e99.
48. Rojanathammanee L, Murphy EJ, Combs CK. Expression of mutant alpha-synuclein modulates microglial phenotype in vitro. J Neuroinflammation 2011; 8:44; PMID:21554732; http://dx.doi.org/10.1186/1742-2094-8-44.
49. Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, et al. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol 2012; 237:318-34; PMID:22750327; http://dx.doi.org/10.1016/j.expneurol.2012.06.025.
50. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VMY. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008; 28:7687- 98; PMID:18650345; http://dx.doi.org/10.1523/JNEUROSCI.0143-07.2008.
51. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem 2008; 283:23542-56; PMID:18566453; http://dx.doi.org/10.1074/ jbc.M801992200.
52. Lynch-Day MA, Mao K, Wang K, Zhao M, Klionsky DJ. The role of autophagy in Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2:a009357; PMID:22474616.
53. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, et al. Dopaminemodified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008; 118:777-88; PMID:18172548.
54. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L. Abberant α-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One 2009; 4:e5515; PMID:19436756; http://dx.doi.org/10.1371/journal.pone.0005515.
55. Yu WH, Dorado B, Figueroa HY, Wang L, Planel E, Cookson MR, et al. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric α-synuclein. Am J Pathol 2009; 175:736- 47; PMID:19628769; http://dx.doi.org/10.2353/ajpath.2009.080928.
56. Winslow AR, Chen CW, Corrochano S, Acevedo- Arozena A, Gordon DE, Peden AA, et al. α-Synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol 2010; 190:1023- 37; PMID:20855506; http://dx.doi.org/10.1083/jcb.201003122.
57. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in α-synuclein models of Parkinson's and Lewy body diseases. J Neurosci 2009; 29:13578- 88; PMID:19864570; http://dx.doi.org/10.1523/JNEUROSCI. 4390-09.2009.
58. Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, et al. Mutant A53T alphasynuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 2011; 286:10814- 24; PMID:21252228; http://dx.doi.org/10.1074/jbc.M110.132514.
59. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249(Suppl 3):III, 1-5; PMID:12528692; http://dx.doi.org/10.1007/s00415- 002-1301-4.
60. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-tograft disease propagation. Nat Med 2008; 14:501-3; PMID:18391963; http://dx.doi.org/10.1038/nm1746.
61. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14:504-6; PMID:18391962; http://dx.doi.org/10.1038/nm1747.
62. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci 2008; 9:741-5; PMID:18769444; http://dx.doi.org/10.1038/nrn2477.
63. Brundin P, Kordower JH. Neuropathology in transplants in Parkinson's disease: Implications for disease pathogenesis and the future of cell therapy. Waxman S, Stein DG, Swaab D, Fields H. Elsevier BV, 2012. 217-237.
64. Dunning CJR, Reyes JF, Steiner JA, Brundin P. Can Parkinson's disease pathology be propagated from one neuron to another? Prog Neurobiol 2012; 97:205-19; PMID:22115849; http://dx.doi.org/10.1016/j.pneurobio.2011.11.003.
65. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007; 33:599-614; PMID:17961138; http://dx.doi.org/10.1111/j.1365-2990.2007.00874.x.
66. Angot E, Steiner JA, Lema Tomé CM, Ekström P, Mattsson B, Björklund A, et al. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One 2012; 7:e39465; PMID:22737239; http://dx.doi.org/10.1371/journal.pone.0039465.
67. Kordower JH, Dodiya HB, Kordower AM, Terpstra B, Paumier K, Madhavan L, et al. Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis 2011; 43:552-7; PMID:21600984; http://dx.doi.org/10.1016/j.nbd.2011.05.001.
68. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VMY. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 2012; 209:975-86; PMID:22508839; http://dx.doi.org/10.1084/jem.20112457.
69. Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchère J, Lakhdar L, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 2012; 33:2225-8; PMID:21813214; http://dx.doi.org/10. 1016/j.neurobiolaging.2011.06.022.
70. Lee HJ, Suk JE, Lee KW, Park SH, Blumbergs PC, Gai WP, et al. Transmission of Synucleinopathies in the Enteric Nervous System of A53T Alpha-Synuclein Transgenic Mice. Exp Neurobiol 2011; 20:181-8; PMID:22355263; http://dx.doi.org/10.5607/en.2011.20.4.181.
71. Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2012; 27:709-15; PMID:21766334; http://dx.doi.org/10.1002/mds.23838.
72. Chanut F. Your synapse or mine? Promiscuous protein exchanges between neighboring synapses. PLoS Biol 2006; 4:e297; PMID:20076633; http://dx.doi.org/10.1371/journal.pbio.0040297.
73. Broadwell RD, Balin BJ. Endocytic and exocytic pathways of the neuronal secretory process and transsynaptic transfer of wheat germ agglutinin- horseradish peroxidase in vivo. J Comp Neurol 1985; 242:632- 50; PMID:2418083; http://dx.doi.org/10.1002/cne.902420410.
74. Mathivanan S, Fahner CJ, Reid GE, Simpson RJ. ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res 2012; 40(Database issue):D1241-4; PMID:21989406; http://dx.doi.org/10.1093/nar/gkr828.
75. Marzo L, Gousset K, Zurzolo C. Multifaceted roles of tunneling nanotubes in intercellular communication. Front Physiol 2012; 3:72; PMID:22514537; http://dx.doi.org/10.3389/fphys.2012.00072.
76. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 2009; 106:20051-6; PMID:19892735.
77. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72:57- 71; PMID:21982369; http://dx.doi.org/10.1016/j.neuron.2011.08.033.
78. Luk KC, Kehm VM, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338:949- 53; PMID:23161999; http://dx.doi.org/10.1126/science.1227157.
79. Editorial. State of aggregation. Nature Publishing Group 2011; 14:399.
80. Aguzzi A, Sigurdson C, Heikenwaelder M. Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 2008; 3:11-40; PMID:18233951; http://dx.doi.org/ 10.1146/annurev.pathmechdis.3.121806.154326.
81. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol 2010; 67:798-801; PMID:20625084; http://dx.doi.org/10.1001/archneurol. 2010.135.
82. Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 2009; 1792:730-40; PMID:18718530; http://dx.doi.org/10.1016/j.bbadis.2008.07.006.
83. Double KL, Reyes S, Werry EL, Halliday GM. Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog Neurobiol 2010; 92:316-29; PMID:20541584; http://dx.doi.org/10.1016/j.pneurobio. 2010.06.001.